Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
BMC Cancer
January 2025
Barts Cancer Institute and Wolfson Institute of Public Health, Mary University of London, John Vane Science Centre, Charterhouse Square, London, Queen, EC1M 6BQ, UK.
Background: Pancreatic cancer (PDAC: pancreatic ductal adenocarcinoma, the commonest form), a lethal disease, is best treated with surgical excision but is feasible in less than a fifth of patients. Around a third of patients presentlocally advanced, inoperable, non-metastatic (laPDAC), whose stadrd of care is palliative chemotherapy; a small minority are down-sized sufficiently to enable surgical excision. We propose a phase II clinical trial to test whether a combination of standard chemotherapy (gemcitabine & nab-Paclitaxel: GEM-NABP) and repurposing All Trans Retinoic Acid (ATRA) to target the stroma may extend progression-free survival and enable successful surgical resection for patients with laPDAC, since data from phase IB clinical trial demonstrate safety of GEM-NABP-ATRA combination to patients with advanced PDAC with potential therapeutic benefit.
View Article and Find Full Text PDFAccommodation microfluctuation in individuals with mTBI and the potential effect of chromatic filter on this parameter.
Vision Res
January 2025
Pacific University, College of Optometry, Forest Grove, OR, United States. Electronic address:
Individuals with mild traumatic brain injury (mTBI) exhibit significant accommodative abnormalities. Accommodation microfluctuation (MFs) plays an important role in the accommodation steady-state control. This study was set to investigate the characteristics of the MFs in mTBI subjects and whether chromatic filter (CF) or neutral density filter (ND) would impact these parameters.
View Article and Find Full Text PDFEnvironmental Challenges and Co-Infection Modulate Resistance and Tolerance Against Trypanosoma Cruzi and Trichinella Spiralis in Rats.
J Exp Zool A Ecol Integr Physiol
January 2025
Laboratorio de Ecología de Enfermedades, Instituto de Ciencias Veterinarias del Litoral (ICIVET LITORAL), Universidad Nacional del Litoral - CONICET, Santa Fe, Santa Fe, Argentina.
To overcome infection, hosts employ two defense strategies: resistance (which limits pathogen fitness), and tolerance (which reduces infection damage). These strategies may be influenced by environmental challenges such as food shortage, social conflict, and co-infections. Here, our objective was to assess defense strategies in rats infected with Trichinella spiralis and/or Trypanosoma cruzi under environmental challenges.
View Article and Find Full Text PDFPrognostic roles of hematological indicators in programmed cell death protein 1/programmed cell death ligand 1 inhibitors for small-cell lung cancer: a retrospective cohort study.
J Thorac Dis
December 2024
Department of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Background: Lung cancer is the main cause of cancer death in the world, with small-cell lung cancer (SCLC) accounting for about 10-15% of all lung cancers. Although programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors represent a major breakthrough in SCLC treatment, only a minority of patients will benefit and there is still a lack of accurate biomarkers to guide clinical application. Inflammation plays a crucial role in tumorigenesis, tumor development, metastasis, and drug resistance, but there is limited research on the predictive value of these inflammatory indicators in SCLC.
View Article and Find Full Text PDFRadiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study.
Transl Lung Cancer Res
December 2024
Department of Medical Oncology, Assistance Publique - Hôpitaux de Paris (AP-HP), Pitié-Salpêtrière Hospital, Institut Universitaire de Cancérologie, CLIP² Galilée, Paris, France.
Background: Oligoprogression (OP) is common in patients with metastatic non-small cell lung cancer (mNSCLC) treated with immune checkpoint inhibitors (ICIs). This study aims to assess the benefit and the safety profile of ablative radiotherapy (RT) for OP in mNSCLC treated with pembrolizumab in first-line setting.
Methods: We retrospectively analyzed records of all consecutive mNSCLC patients who underwent treatment with pembrolizumab (+/- chemotherapy) in first-line setting and developed an OP treated with ablative RT while continuing pembrolizumab, in a French Hospital from 2019 to 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!